Faculty profile

Tommy Moya

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Tommy Moya

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
48 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

194

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
British journal of haematology · 2026
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.
JCO oncology practice · 2026
Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy · 2026 · senior author

All 56 publications

56 publications.

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A

British journal of haematology20263 citations

DOI: 10.1111/bjh.70380 PMID: 41747740

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Desai N, Rodriguez-Rodriguez S, Chen C, Al-Shaibani E, Alfaro Moya T, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DDH, Kumar R, Mattsson J, Law AD

JCO oncology practice20261 citations

DOI: 10.1200/op-25-01308 PMID: 42372210

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Rodriguez-Rodriguez S, Salas MQ, Desai N, Al-Shaibani E, Novitzky-Basso I, Pasic I, Viswabandya A, Michelis FV, Mattsson J, Kim DDH, Kumar R, Moya TA

Transplantation and cellular therapy20261 citationsSenior author

DOI: 10.1016/j.jtct.2026.01.026 PMID: 41571188

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Rodriguez-Rodriguez S, Chiarello C, Desai N, Remberger M, Chen C, Al-Shaibani E, Alfaro Moya T, Law AD, Pasic I, Viswabandya A, Michelis FV, Kim DDH, Kumar R, Mattsson J, Novitzky-Basso I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.03.015 PMID: 41839367

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.05.018 PMID: 42142626

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Chiarello C, Singhabahu S, Remberger M, Chen C, Moya TA, Al-Shaibani E, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.10.002 PMID: 41062023

Frailty-comorbidity discordance and non-relapse mortality after allogeneic hematopoietic cell transplantation.

Nihar Desai, Tommy Alfaro Moya, Ivan Pašić, Carol Chen, Eshrak Al‐Shaibani, Arjun Law, Igor Novitzky-Basso, Fotios Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Jonas Mattsson, María Queralt Salas, Rajat Kumar

Journal of Clinical Oncology2026

DOI: 10.1200/jco.2026.44.16_suppl.6552

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.

Salas MQ, Alfaro Moya T, Pasic I, Baile González M, Gómez MA, Fox L, Pérez Artigas MDM, Santamaría A, Quintela González MDC, Sánchez Salinas A, Salmerón Camacho JM, Illana Álvaro V, Abdallahi-Lefdil Z, Navascues JC, Pardo L, Fernández-Luis S, Vega Suárez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo García I, Mussetti A, Lavilla E, Lopez-Marín J, Filaferro S, Balsalobre P, Bento L, Law A, Viswabandya A, Michelis FV, Mattsson J, Alibhai S, Rovira M, Wang Kim DD, Sureda A, Kumar R

EClinicalMedicine2026Open Access

DOI: 10.1016/j.eclinm.2025.103753 PMID: 41567713

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.

Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Kumar R, Kim DDH, Lipton JH, Mattsson J, Law AD

Blood advances202539 citationsOpen Access

DOI: 10.1182/bloodadvances.2024014781 PMID: 39565954

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.

Reid KT, Colpitts SJ, Mathews JA, Santos Carreira A, Murphy JM, Borovsky DT, Jegatheeswaran S, Cui W, Alfaro Moya T, Sachewsky N, An J, Xia Y, Mortha A, Lee JB, Zhang L, Novitzky-Basso I, Mattsson J, Crome SQ

Cell reports202512 citationsOpen Access

DOI: 10.1016/j.celrep.2024.115102 PMID: 39721022

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Tommy Moya

Research

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Frailty-comorbidity discordance and non-relapse mortality after allogeneic hematopoietic cell transplantation.

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.

Frequent collaborators

Tommy Alfaro Moya

Jonas Mattsson

Igor Novitzky-Basso

Rajat Kumar

Auro Viswabandya

Ivan Pasic

Eshrak Al-Shaibani

Wilson Lam

Shabbir Alibhai

Sarah Crome

Mohamed Elemary

Arthur Mortha

Fotios Michelis

Dennis Kim

Li Zhang

Phedias Diamandis

Neesha Dhani

Michael Kennah

Pamela Ohashi

Christopher Lemieux

Jennifer Bell

Tommy Moya

Research

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Frailty-comorbidity discordance and non-relapse mortality after allogeneic hematopoietic cell transplantation.

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T&#xa0;cell responses.

Frequent collaborators

Tommy Alfaro Moya

Jonas Mattsson

Igor Novitzky-Basso

Rajat Kumar

Auro Viswabandya

Ivan Pasic

Eshrak Al-Shaibani

Wilson Lam

Shabbir Alibhai

Sarah Crome

Mohamed Elemary

Arthur Mortha

Fotios Michelis

Dennis Kim

Li Zhang

Phedias Diamandis

Neesha Dhani

Michael Kennah

Pamela Ohashi

Christopher Lemieux

Jennifer Bell

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.